【摘要】 本文对BCG，BCG＋IL－2膀胱灌注预防膀胱癌术后复发的疗效进行了分析，74例膀胱癌分为两组。一组40例单用BCG（150mg），另一组34例BCG（100mg）＋IL－2（20000Iu）。BCG组随访18～72月，平均30．9月，无肿瘤复发率80％（32／40），BCG＋IL－2组随访16～7O月，平均29．4月，无肿瘤复发率88．3％（3O／34），两组比较有显著性（P<0．01）。结果表明，无论单独用BCG或BCG＋IL－2联合应用，疗效都十分肯定，而BCG＋IL－2组更优，可减少BCG用量，毒副反应小。更多还原

【Abstract】 Railway Medical College in Xuzhou, Xuzhou 221009For the prevention of tumor recurrence,intravesical instillation of only 150mg BCGwas instituated postoperatively in 40 cases of bladder cancer and intravesical instillationof a combination of 20000 unites of IL-2 and 100mg of BCG in another 34. In the BCGgroup, 80% (32/40) have been free of tumor for a mean time of 30. 9 months (follow upranging from 18 to 72 months) and in the combination of BCG and IL-2 group, 88. 3%(30/34) have been free of tumor for a mean time of 29. 4% months (follwo up rangingfrom 16 to 70 months). Comparing the results of two groups, it is striking (P<0.01).The results revealed that BCG or combination BCG and IL-2 intravesilal instillation inthe prevention of tumor recurrence, which effect were very definited. The later groupwhat is more dominant, it decreased the dose of BCG and the side-effect minor.更多还原